Vaxcell Bio Therapeutics

VaxcellBio was founded in 2010 and is dedicated to the development and commercialization of cell-based anti-cancer immunotherapies, cancer vaccines, and anti-cancer protein drugs. The company's CEO, Je-Jung Lee, is a hematologist. Currently, VaxcellBio’s NK (Natural Killer) cell-based liver cancer treatment has completed Phase II clinical trials and is preparing for product registration.